Can UCB's Bimekizumab Go From Last To First In Psoriasis?
Skin Clearance Data Tops Rivals
Although it is playing catching up on well-established rivals, especially Novartis's Cosentyx, the Belgian company believes that bimekizumab provides both a fast and durable response for psoriasis patients, driven by impressive PASI 100 rates.
You may also be interested in...
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.
With the drug demonstrating superiority over approved psoriasis therapies such as Cosentyx, Stelara and Humira in clinical trials, UCB's bimekizumab will shortly compete against these well-entrenched rivals on the European market, following a thumbs-up from the CHMP.
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.